Trastuzumab radioimmunoconjugates - promising strategy for selective anticancer therapy

Apostolova, Paulina and Arev, Marija and Ristovska, Mila and Janevik-Ivanovska, Emilija (2021) Trastuzumab radioimmunoconjugates - promising strategy for selective anticancer therapy. In: Adaptation of the tumor and its ecosystem to radiotherapies - Mechanisms, imaging and therapeutic approaches, 22-25 Sept 2021, France.

[thumbnail of Book of abstract_2021_final A5 (1).pdf] Text
Book of abstract_2021_final A5 (1).pdf - Published Version

Download (13MB)
[thumbnail of Final - Trastuzumab radioimmunoconjugates – promising strategy for selective anticancer therapy.pdf] Text
Final - Trastuzumab radioimmunoconjugates – promising strategy for selective anticancer therapy.pdf - Published Version

Download (300kB)
[thumbnail of Final - Trastuzumab radioimmunoconjugates - presentacija.pdf] Slideshow
Final - Trastuzumab radioimmunoconjugates - presentacija.pdf - Published Version

Download (1MB)

Abstract

Monoclonal antibody Trastuzumab is the first humanized approved antibody for tratment of HER-2 positive breast cancer. Led by its promising indication, we made further improvemetns to prepare freeze-dried immunogates with bifunctional chelators, ready to use kit formulation for radiolabeling.
Formulation of freeze dried immunoconjugates of trastuzumab was prepared after purification of commercially available drug, already used for treatment, using bifunctional chelating agent (BFCA) with acyclic (1B4M-DTPA) and macrocyclic (DOTA) structure.
A several chemical techniques have been used to determine the stability and retained immunoreactivity of the antibody in the formulated immunoconjugates and after their labelling with radioactive and non-radioactive isotopes.
The appearance of two bands of fragments in SDS-PAGE gels in lyophilized and labeled conjugates have shown retained secondary structure. The presence of characteristic amide bands in IR spectra and Raman spectra have indicated that all samples have retained native secondary structure. An average of 4.3-5.3 groups linked to the antibody determined by MALDI analysis helped in the decision of molar ratio Ab: BFCA and successful labeling.
Stability of freeze dried immunoconjugates (in molar ratio 1:20) were characterized by HPLC-UV and yield of labelling with 177Lu and 90Y by ITLC-SG.
According to all obtained results and previous experiens related to the freeze dried formulation of antibody conjugates, we have hope that this approach can give a distinctive contribution in the fields of radioimmunotherapy using beta emitters and alpha as well.

Item Type: Conference or Workshop Item (Speech)
Subjects: Medical and Health Sciences > Basic medicine
Divisions: Faculty of Medical Science
Depositing User: Paulina Apostolova
Date Deposited: 18 Feb 2022 08:54
Last Modified: 18 Feb 2022 08:54
URI: https://eprints.ugd.edu.mk/id/eprint/29470

Actions (login required)

View Item View Item